Daniel A. Ermann, MD

Articles by Daniel A. Ermann, MD

Image Credit: © TheWaterMeloonProjec - stock.adobe.com

Dr Ermann on Real-World Data for Zanubrutinib vs Acalabrutinib in Older CLL

July 16th 2026

Daniel Ermann, MD, discusses findings from a real-world study of first-line BTK inhibitors in older patients with chronic lymphocytic leukemia.

Image Credit: © LELISAT - stock.adobe.com

Dr Ermann on Data for Real-World Treatment Burdens in Older Patients with CLL

ByDaniel A. Ermann, MD

July 15th 2026

Daniel Ermann, MD, discusses data for real-world treatment burdens among older patients with chronic lymphocytic leukemia.

Image Credit: © Om.Nom.Nom - stock.adobe.com

Dr Ermann on BTK Inhibitor Selection in Treatment-Naive CLL

ByDaniel A. Ermann, MD

July 15th 2026

Daniel Ermann, MD, discusses improvements shown in real-world data for zanubrutinib compared with acalabrutinib in treatment-naive CLL.

Real-World Outcomes Among Medicare Beneficiaries Treated With First-Line Bruton Tyrosine Kinase Inhibitors for Chronic Lymphocytic Leukemia

ByDaniel A. Ermann, MD

June 26th 2026

Daniel A. Ermann, MD, reviews a large Medicare Fee-for-Service analysis showing zanubrutinib was associated with longer real-world treatment duration, time to next treatment, and overall survival vs acalabrutinib and ibrutinib in older patients with first-line CLL.

Closing Thoughts & Future Directions

ByCatherine C. Coombs, MD,Daniel A. Ermann, MD,Nicole Lamanna, MD,Javier A. Pinilla-Ibarz, MD, PhD,Joanna M. Rhodes, MD, MSCE,Mazyar Shadman, MD, MPH

January 27th 2026

Experts discuss advancements in CLL treatment, highlighting pirtobrutinib's role and the potential of CAR T-cells and bispecific therapies.

Co-Management, Community Partnerships & Longitudinal Care

ByCatherine C. Coombs, MD,Daniel A. Ermann, MD,Nicole Lamanna, MD,Javier A. Pinilla-Ibarz, MD, PhD,Joanna M. Rhodes, MD, MSCE,Mazyar Shadman, MD, MPH

January 27th 2026

Experts discuss the role of MRD testing in CLL treatment, emphasizing personalized approaches and the importance of continuity in patient care.

Resistance Testing, Peripheral vs. Tissue Sampling, and Clinical Monitoring

ByCatherine C. Coombs, MD,Daniel A. Ermann, MD,Nicole Lamanna, MD,Javier A. Pinilla-Ibarz, MD, PhD,Joanna M. Rhodes, MD, MSCE,Mazyar Shadman, MD, MPH

January 20th 2026

Experts discuss the impact of real-world data on CLL treatment sequencing, highlighting survival outcomes and the importance of targeted therapies.

Broader Measures of Treatment Success & Venetoclax Retreatment

ByCatherine C. Coombs, MD,Daniel A. Ermann, MD,Nicole Lamanna, MD,Javier A. Pinilla-Ibarz, MD, PhD,Joanna M. Rhodes, MD, MSCE,Mazyar Shadman, MD, MPH

January 20th 2026

Explore the latest insights on venetoclax retreatment effectiveness and its impact on patient outcomes in chronic lymphocytic leukemia therapy.

Comparative Data, Safety Profiles, and Sequencing with Pirtobrutinib and Other BTKs

ByCatherine C. Coombs, MD,Daniel A. Ermann, MD,Nicole Lamanna, MD,Javier A. Pinilla-Ibarz, MD, PhD,Joanna M. Rhodes, MD, MSCE,Mazyar Shadman, MD, MPH

January 13th 2026

Experts discuss the implications of recent studies on pirtobrutinib, comparing its efficacy and safety against other BTK inhibitors for CLL treatment.

The Rise of Pirtobrutinib and Its Clinical Implications in CLL

ByCatherine C. Coombs, MD,Daniel A. Ermann, MD,Nicole Lamanna, MD,Javier A. Pinilla-Ibarz, MD, PhD,Joanna M. Rhodes, MD, MSCE,Mazyar Shadman, MD, MPH

January 13th 2026

Experts discuss strategies for selecting second-line therapies in CLL, emphasizing treatment history, patient response, and genetic factors.

Time-Limited Therapy, MRD, and Treatment Discontinuation

ByCatherine C. Coombs, MD,Daniel A. Ermann, MD,Nicole Lamanna, MD,Javier A. Pinilla-Ibarz, MD, PhD,Joanna M. Rhodes, MD, MSCE,Mazyar Shadman, MD, MPH

January 6th 2026

Experts discuss the balance of safety, efficacy, and logistics in treatment choices, highlighting the evolving landscape of BTK inhibitors and patient preferences.

Managing Early Relapse of CLL & Treatment Selection After Frontline Therapy

ByCatherine C. Coombs, MD,Daniel A. Ermann, MD,Nicole Lamanna, MD,Javier A. Pinilla-Ibarz, MD, PhD,Joanna M. Rhodes, MD, MSCE,Mazyar Shadman, MD, MPH

January 6th 2026

Experts discuss the importance of patient-specific factors and preferences in selecting first-line treatments for CLL.

First-Line Therapy Decisions & Risk Stratification in CLL

ByCatherine C. Coombs, MD,Daniel A. Ermann, MD,Nicole Lamanna, MD,Javier A. Pinilla-Ibarz, MD, PhD,Joanna M. Rhodes, MD, MSCE,Mazyar Shadman, MD, MPH

December 22nd 2025

Experts discuss evolving treatment strategies for CLL, highlighting the balance between time-limited and continuous therapies for optimal patient outcomes.

Introductions & Framework for CLL Treatment

ByCatherine C. Coombs, MD,Daniel A. Ermann, MD,Nicole Lamanna, MD,Javier A. Pinilla-Ibarz, MD, PhD,Joanna M. Rhodes, MD, MSCE,Mazyar Shadman, MD, MPH

December 22nd 2025

Explore the evolving treatment landscape for Chronic Lymphocytic Leukemia, focusing on BTK and BCL2 inhibitor strategies and biomarker testing insights.